# reload+after+2024-01-21 03:47:11.008553
address1§7000 Marina Blvd
city§Brisbane
state§CA
zip§94005
country§United States
phone§510 970 6000
website§https://www.sangamo.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
fullTimeEmployees§478
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D.', 'age': 60, 'title': 'CEO, President & Director', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 1171354, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Prathyusha  Duraibabu CPA, M.B.A.', 'age': 44, 'title': 'Senior VP, CFO & Principal Accounting Officer', 'yearBorn': 1979, 'fiscalYear': 2022, 'totalPay': 628080, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Amy  Pooler Ph.D.', 'title': 'Head of Research', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Gregory  Davis Ph.D.', 'title': 'Head of Technology', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Aron  Feingold', 'title': 'Head of Corporate Communications & Investor Relations Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Scott B. Willoughby', 'age': 48, 'title': 'Senior VP, General Counsel & Corporate Secretary', 'yearBorn': 1975, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Whitney  Jones', 'title': 'Chief People Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Nathalie  Dubois-Stringfellow Ph.D.', 'age': 61, 'title': 'Senior VP & Chief Development Officer', 'yearBorn': 1962, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Lisa  Rojkjaer M.D.', 'age': 57, 'title': 'Chief Medical Officer', 'yearBorn': 1966, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Phillip  Ramsey', 'title': 'Head of Technical Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§6
boardRisk§3
compensationRisk§7
shareHolderRightsRisk§2
overallRisk§4
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.039
priceToSalesTrailing12Months§0.39973956
currency§USD
dateShortInterest§1702598400
forwardEps§-0.48
pegRatio§0.02
exchange§NMS
quoteType§EQUITY
shortName§Sangamo Therapeutics, Inc.
longName§Sangamo Therapeutics, Inc.
firstTradeDateEpochUtc§955027800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§204a90d5-6f3d-377d-ac4a-5d324a9a4123
gmtOffSetMilliseconds§-18000000
targetHighPrice§8.0
targetLowPrice§1.0
targetMeanPrice§3.17
targetMedianPrice§2.5
recommendationMean§2.2
recommendationKey§buy
numberOfAnalystOpinions§6
quickRatio§2.761
grossMargins§-0.2185
ebitdaMargins§-0.45049998
trailingPegRatio§None
